Give your opinion on a genetically modified medicine for haemophilia B
The FPS Public Health and the FAMHP invite you to participate in the public consultation on a clinical trial of the genetically modified medicine CSL222 for the treatment of haemophilia B. The public consultation will take place from 28 April to 28 May 2025.